Related Experiment Video
Updated: Aug 4, 2025
07:15
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
499
[Granulomatosis with polyangiitis: what's new?]
Maxime Ringwald1, Dehlia Chevalley2, Cédric Bongard3
1Service d'immunologie et allergie, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Revue Medicale Suisse
|April 5, 2023
Summary
Granulomatosis with polyangiitis (GPA) is a common ANCA-associated vasculitis affecting ENT, lungs, and kidneys. Early diagnosis and multidisciplinary treatment are crucial to manage relapses and reduce medication toxicity.
Area of Science:
- Rheumatology
- Immunology
- Nephrology
Context:
- Granulomatosis with polyangiitis (GPA) is the most common antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
- Incidence rates range from 10 to 20 cases per million annually.
- Clinical presentations vary, frequently involving the ears, nose, throat (ENT), lungs, and kidneys.
Purpose:
- To outline the diagnostic challenges and therapeutic strategies for GPA.
- To emphasize the pathogenic role of ANCA in neutrophil activation and vascular damage.
- To highlight the importance of a multidisciplinary approach in managing GPA.
Summary:
- ANCA are key diagnostic markers, though serology can be negative in GPA limited to airways.
- Treatment involves induction and maintenance phases using corticosteroids and immunosuppressants.
- Therapeutic goals include minimizing relapse risk and reducing corticosteroid-related toxicity.
Impact:
- Improved understanding of GPA pathogenesis and clinical manifestations.
- Guidance for timely diagnosis and effective management strategies.
- Framework for optimizing treatment outcomes and patient quality of life in GPA.
